SOCIAL MEDIA BROADCAST TWO

Advances in Chronic Lymphocytic Leukemia Care:
A Focus on Empowering the Multidisciplinary Community-Based Team

Faculty

Erin Fahey-Harrison, PA-C, NP, PA
Sr. Instructor, Medicine-Hematology
University of Colorado Hospital
Aurora, CO

Program Overview

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) management demands a patient-centered approach, focusing on symptomatic patients or those at high risk of progression. This program will cover the latest risk classification criteria and clinical guidelines, emphasizing the transition from chemo-immunotherapy to targeted therapies like Bruton kinase inhibitors (BTKi), anti-CD20 monoclonal antibodies, and BCL2 inhibitors.

Given the incurable nature of CLL/SLL, patients often require multiple treatments, each with specific benefits and risks. The program will highlight evidence-based practices and a multidisciplinary approach to enhance patient outcomes, supported by case scenarios demonstrating the application of emerging therapies in clinical practice.

Target Audience

This program is intended for community-based medical hematologists/oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with CLL. 

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • DISCUSS therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL. 
  • EVALUATE the evolving role of current and emerging therapeutics for CLL/SLL. 
  • DESCRIBE how to manage treatment-related symptoms in patients with CLL/SLL.  
  • OUTLINE multidisciplinary management plans for patients with CLL/SLL to optimize quality of life and address racial and age-related disparities in care. 

Accreditation

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium Continuing Education (Iridium). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours including 0.0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 70% or higher


A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Disclosures

Disclosures of Relevant Financial Relationships


​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Erin Fahey-Harrison, PA-C, NP, PA
Nothing to disclose.

The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This educational activity is supported by independent educational grants from Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC and AbbVie Inc.

Activity Credit Amount: 0.5
Credit Type: ACCME, ANCC
Release: November 30, 2024
Expiration: November 30, 2025

info@iridiumce.com